Last reviewed · How we verify
Group III - Serratiopeptidase Group
Serratiopeptidase is a serine protease enzyme that breaks down non-structural proteins and fibrin, reducing inflammation and promoting tissue repair.
Serratiopeptidase is a serine protease enzyme that breaks down non-structural proteins and fibrin, reducing inflammation and promoting tissue repair. Used for Post-operative inflammation and swelling, Musculoskeletal pain and inflammation, Sinusitis and ENT inflammation.
At a glance
| Generic name | Group III - Serratiopeptidase Group |
|---|---|
| Sponsor | Zahoor khan |
| Drug class | Serine protease enzyme |
| Target | Non-structural proteins, fibrin, inflammatory mediators |
| Modality | Small molecule |
| Therapeutic area | Inflammation, Pain Management, Orthopedics |
| Phase | Phase 3 |
Mechanism of action
Serratiopeptidase is a proteolytic enzyme derived from Serratia marcescens bacteria that selectively degrades inflammatory proteins, fibrin, and damaged tissue while sparing healthy tissue. It reduces swelling, improves blood flow, and facilitates the clearance of inflammatory exudate, making it useful in conditions characterized by inflammation and tissue damage.
Approved indications
- Post-operative inflammation and swelling
- Musculoskeletal pain and inflammation
- Sinusitis and ENT inflammation
- Fibrocystic breast disease
Common side effects
- Gastrointestinal upset
- Nausea
- Allergic reactions
- Bleeding (rare)
Key clinical trials
- Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group III - Serratiopeptidase Group CI brief — competitive landscape report
- Group III - Serratiopeptidase Group updates RSS · CI watch RSS
- Zahoor khan portfolio CI